This Article Full Text Full Text (PDF) All Versions of this Article: 2006-0331TRv1 36/2/158    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fredenburgh, L. E. Articles by Mitsialis, S. A. Search for Related Content PubMed PubMed Citation Articles by Fredenburgh, L. E. Articles by Mitsialis, S. A.

The Role of Heme Oxygenase-1 in Pulmonary Disease

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital; and Division of Newborn Medicine, Children's Hospital, Boston, Massachusetts

Correspondence and requests for reprints should be addressed to Laura E. Fredenburgh, Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. E-mail: lfredenburgh{at}partners.org

Abstract

Heme oxygenase (HO)-1, the inducible isoform of heme oxygenase, is a cytoprotective enzyme that plays a central role in the defense against oxidative and inflammatory insults in the lung. HO-1 catalyzes the degradation of heme, a potent oxidant, into biliverdin, iron, and carbon monoxide (CO). These downstream products of heme catabolism have recently been found to mediate the antioxidant, antiapoptotic, antiproliferative, vasodilatory, and anti-inflammatory properties of HO-1. Although absence of HO-1 is rare in humans, a number of HO-1 promoter polymorphisms have been identified that may influence HO-1 expression in vivo and lead to disease states. This review will summarize studies that implicate HO-1 and heme metabolites in the pathophysiology of pulmonary disease and discuss recent advances in the therapeutic applications of HO-1.

Key Words: HO-1 • polymorphism • ARDS • pulmonary hypertension • COPD

CLINICAL RELEVANCE HO-1 plays a key role in the defense against oxidative and inflammatory insults in the lung. This review summarizes studies that implicate HO-1 in pulmonary disease and recent advances in the therapeutic applications of HO-1.

 

This article has been cited by other articles:

				I-T. Lee, S.-W. Wang, C.-W. Lee, C.-C. Chang, C.-C. Lin, S.-F. Luo, and C.-M. Yang Lipoteichoic Acid Induces HO-1 Expression via the TLR2/MyD88/c-Src/NADPH Oxidase Pathway and Nrf2 in Human Tracheal Smooth Muscle Cells J. Immunol., October 1, 2008; 181(7): 5098 - 5110. [Abstract] [Full Text] [PDF]

				D Goven, A Boutten, V Lecon-Malas, J Marchal-Somme, N Amara, B Crestani, M Fournier, G Leseche, P Soler, J Boczkowski, et al. Altered Nrf2/Keap1-Bach1 equilibrium in pulmonary emphysema Thorax, October 1, 2008; 63(10): 916 - 924. [Abstract] [Full Text] [PDF]

				M Siedlinski, C C van Diemen, D S Postma, and H M Boezen Heme oxygenase 1 variations and lung function decline in smokers: proof of replication J. Med. Genet., June 1, 2008; 45(6): 400 - 400. [Full Text] [PDF]

				E. J. Cornish, B. J. Hurtgen, K. McInnerney, N. L. Burritt, R. M. Taylor, J. N. Jarvis, S. Y. Wang, and J. B. Burritt Reduced Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Independent Resistance to Aspergillus fumigatus in Alveolar Macrophages J. Immunol., May 15, 2008; 180(10): 6854 - 6867. [Abstract] [Full Text] [PDF]

				H. Zhang and H. J. Forman Acrolein Induces Heme Oxygenase-1 through PKC-{delta} and PI3K in Human Bronchial Epithelial Cells Am. J. Respir. Cell Mol. Biol., April 1, 2008; 38(4): 483 - 490. [Abstract] [Full Text] [PDF]

				M. A. Perrella Heme Oxygenase-1: A Multifaceted Triple-Threat Molecule Am. J. Respir. Cell Mol. Biol., February 1, 2007; 36(2): 137 - 137. [Full Text] [PDF]